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The pharmacologic and clinical effects of the 5-lipoxygenase 
inhibitor, lonapalcne, have been determined in a double-
blind, placebo-controlled, topical study in ten volunteers 
with p~oriasis. A statistically significant clinical improve-
ment was seen in lesions treated with 2% lonapalene oint-
ment a~ compared wtth vehicle-treated sites. Although there 
was a statistically significant reduction in the levels of mate-
rial similar or identical to the chemoattractant arachidonate 
5-lipoxygenase product, leukotriene B4, in skin chamber 
fluid samples from lonapalene versus vehicle treated lesions, 
no significant reduction in arachidonic acid or 12-hydroxy-
D etermination of the relevance of a locally produced b1olog1cally acnve substance in rhe pathogeneSIS of a disease process requires the satisfaction of certain criteria, mo~t of which demand in vivo experimen-tation. As previously reviewed [ 1), these criteria in-
clude 1) demomtrarion of the release of the substance in vivo by 
analysis of samples from the disease process; 2) demonstration that 
the substance is able to reproduce in vivo, in appropriate doses, that 
aspect of the d1sease proces~ for which it is thought to be responsi-
ble; 3) demonstration of mechanisms for the local production of the 
substance; and 4) demonstration that specific inhibitors of the for-
mation or effect~ of the ~ubsrance, administered in v1vo, eliCit appro-
pnare therapeutic respomes. Further useful infonnation concerning 
the pathogeniC Importance of a substance in a particular disease may 
be obramed by deterrmning the specificity of production of the 
suh~tance to the d1sease, and by derennining the relative amounts of 
other compound~ With sinular biologic properties in samples from 
the d1sease proces~. 
The arachiJon1c acid {AA) 5-lipoxygenase mctabohre, leuko-
triene B. (L TB.) has been imphcared m the pathogenesis of psonaSJS 
for several reasons. It possesses potent neutrophil chemoarrractant 
properties 111 VItro (2 ,3] and has been identified. in samples from 
psoriatic lestons m concentrations significantly higher than in rhme 
from chmcally normal skin [ 4 - 7]. Furthermore, topical application 
of L TB4 to the skm of normal volunteers induces the formation o f 
inrraepidermal neutrophil m1croabsccsses, mimicking to some ex-
tent the mflammarory infiltrate in psoriatic lesions [8]. While this 
evidence supports a role for L TB. in psoriasis, other findings suggest 
that 1ts local production is unlikely to be a pnmary pathogenic 
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5,8, I 0 , 14-eicosatetraenoic acid was seen. The reduction in 
leukotriene B4 equivalents occurred before significant clini-
cal improvement in lesions was seen. This and the selectivity 
of the pharmacologic response suggest that the therapeutic 
effect of topical lonapalene in psoriasis might be related to 
inhibition of lcukotriene B4 synthesis. The~e results support 
the view that 5-lipoxygenase inhibitors may be useful in the 
treatment of psoriasis, and that leukorriene B4 is a relevant 
mediator of the pathology of this di~ease. J Invest Dmnatol 
95:50-54, 1990 
phenomenon. These include the fact that irs formation is nor spe-
ci fic to psoriatic lesions, LTB.-like material havmg been recovered 
from atopic dermatitis [7] and allergic contact dermatitis [9]. Fur-
thermore, single and multiple applications of L TB. to the skin of 
normal volunteers and to the clinically uninvolved skin of patients 
with psoriasis failed to el icit psoriatic lesions, multiple applications 
being associated with a localized stare of decreased responsiveness 
[tO]. Finally, LTB. is nor the only neutrophil chemoartractant iso-
lated from psoriatic lesions. Also recoverc:d werc: biOlogically active 
amounts of 12-hydroxy-5,8, 1 0,14-eicosatetraenoic acid (12-
HETE) [11,12], especially the 12(R)-isomer [13]; platelet activating 
factor [14,15]; C5a des arg-like material [16,17, 18]; an unidentified 
monohydroxy fatty actd-like chemokinetic lil?1d (19]; and a group 
of novel chemoattracrant cytokmes [17,18,20] wh1ch appear robe 
related ro inrerleukin 8 [21]. W hile these findmgs suggest that locaJ 
release of L Tl34 is not a primary pathogenic phenomenon in psoria-
SIS, they do not exclude the possibility that LTB. may play an im-
portant role, together with other phenomena, m a combination of 
events that culminate m a psoriatic lesion. The importance of 5-li-
poxygenase in psoriasis is also enhanc~d by the finding of increased 
levels of the vasoactive sulphidopepride 5-lipoxygenase products, 
LTC. and D •• in samples from psoriatic bions [22]. 
Of the var1ous criteria described above, one of the most difficult 
to satisfy 1s that requiring demonstration of an appropriate thera-
peutic response following in vivo administration of mediator spe-
Cific syntht' tase inhibitors or receptor antagonists. Difficulties arise 
because of the lack of pham1acologically ~pecific agents of sufficient 
proven safety for clinical use. Furthermore, compounds which ex-
hibit appropriate pharmacologic effects in the laboratory may lack 
these effects when administered to humans. For example, 
L652,343, an active 5-lipoxygenase inhibitor in vitro, failed to re-
duce L TB. levels in samples from lesions when administered oraJly 
ro volunteer~ with psoriasis (23). Therefore. it becomes important to 
determme whether the administration of a spec1fic synthetase in-
hibitor not only causes reduction in the le~JOnal level~ of the appro-
pnare mediator, bur also whether any reducnon occurs prior to the 
onset of a s1gnificanr therapeunc response, such that the therapeutic 
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respon~e may possibly be attributed to inhibition of synthesis of the 
mediator. 
Lonapalene {6-chloro-2, 3-dimethoxynapthalene-1,4-dio-diace-
tate, RS 43179) inhibits the production of 5-lipoxygenase metabo-
lites by ionophore-stimulated human polymorphonuclear leuko-
cytes and by high-speed supernatants from rat basophilic leukemia 
cells with IC 50 values of approximately 20 and 0.5 ,uM, respectively 
[24]. Topically applied lonapalene also caused dose-dependent inhi-
bition of AA-induced mouse ear oedema [25]. In contrast, concen-
trations up co 200 ,uM were inactive or slightly stimulatory towards 
human platelet, sheep vesicular gland, and mouse epidermal cy-
clooxygenase, platelet and mouse epidermal 12-lipoxygenase, and 
soya bean 15-lipoxygenase [24]. Topical application of lonapalene 
in a Scholtz-Dumas bioassay [26] in volunteers with psoriasis dem-
onstrated antipsoriatic activity (25]. This effect was confirmed in 
double-blind therapeutic trials, in which lonapalene appeared co be 
as efficacious as a potent steroid [27 ,28]. 
We now report the resu lts of a double-blind, placebo-conrrolled, 
integrated pharmacologic and clinical study, in which the levels of 
LTB~. 12-HETE, and their precursor, AA, have been measured in 
samples from psoriatic lesions during trearment with topically ap-
plied lonapalene. To our knowledge, this is the first reported study 
of its kind, with a 5-lipoxygenase inhibitor, either in disease of the 
skin or any other human organ. 
MATERIALS AND METHODS 
Patients Nine male patients and one female patient, aged 21-57 
years (mean, 44.4 years), participated in the study. All had had 
psoriasis for at least one year, and the lesions involved 10%-40% of 
the body surface. The patients had not received systemic treatment 
for their psoriasis at any time, and had not applied any active topical 
therapy for 2 weeks prior to the study. using only emulsitying 
ointmenr BP as an emollient and soap substitute. No systemic medi-
cation of any kind was taken during the trial. Ethical committee 
approval was granted and informed consenr obtained from each 
volunteer before the study. 
Treatment Lonapalene ointment {2% w fw) and its placebo ve-
hicle containing propylene glycol, propylene carbonate, glyceryl 
monostearate, white wax, and petrolatum were used. Symmetrical 
areas of at least 100 cm2 on the limbs were designated for paired 
companson. Patients were supp!Jed with color-coded tubes, and 
active drug and placebo were applied in a randomized, double-blind 
manner to the designated symmetrical lesions. Paired applications 
were made by the patient~ twice daily without occlusion for 28 d, 
and the patients were asked co wash their hands after each applica-
tion. An untreated lesion sited at least 10 em away from the test 
areas was also observed in each case. The designated areas were not 
exposed to sunlight during the study, and bland emollient was ap-
plied to other areas only if necessary. 
Double-Blind Clinical Assessment Before rrearment, and on 
days 4, 14, and 28 after starting treatment, each designated area was 
evaluated visually for erythema, induration, and scaling by the same 
investigatOr throughout the study. Each sign was arbitrarily scored 
on a scale from 0-3 (0 = no abnormality, I = mild, 2 = moderate, 
and 3 =severe changes), allowing a combined maximal score of 9 
per designated site. Each patient also underwent routine haemato-
logic and biochem1cal testing and urinalysis immediately before and 
after the trial. 
Lesion Sampling On days 4 and 14 after starting treatment, 
designated lesions were sampled by using a skin chamber method, as 
previously described [5). Briefly, lesions were gently abraded with a 
scalpel blade to yield a 2-cm diameter glistening area with minimal 
punctuate bleeding. An acrylic cylindrical chamber ( 19 mm inter-
nal diameter) was fixed to each abrasion with cyanoacrylate adhe-
sive and I ml sterile phosphate-buffered saline (PBS) added. This 
was discarded after 5 min and replaced with a further 1 ml PBS for 
30 min. Two chamber fluid samples were obtained from each desig-
nated area at each rime point, pooled, and immediately centrifuged 
LONAPALENE (RS 43179) IN PSORIASIS 51 
to remove blood cells. Supernatant was divided into two 0.9 ml 
samples {A and B), one of which (A) was mixed with deucerated 
internal standards (100 ng f5,6,8,9,11,12,14,15-2H) AA and 2 ng 
(5 ,6,8,9,11,12,14,1VH]I2-HETE dissolved in 20 ,ul methanol). 
Both samples were then snap frozen in liquid N 2 and stored at 
-2o·c. 
Sample Purification and Assay Each sample containing deu-
terated internal standards (A) was thawed, acidified with 25 ,ul gla-
cial acetic ac1d, and partitioned three times with 0.8 ml ethyl ace-
tate. The organic phases were separated by centrifugation, pooled in 
silanized glassware, and evaporated under a stream ofN2• Following 
vacuum desiccation for 30 min, the residue was redissolved in 1 m1 
methanol and partitioned rwice with 1.3 ml n-heptane to remove 
non-polar material. The upper hexane phases were discarded and 
the methanolic layer evaporated under a stream of N2• The residue 
was purified by reversed-phase high-performance liquid chroma-
tography (HPLC) on a 25 em X 4.9 mm Nucleosil 5 C18 column 
{Hichrom, Reading, UK) eluted with methanol/water/acetic acid 
(93:7:0.01, by vol) at I ml min-•. A !-min fraction (elution rime 
approximately 4.5 - 5.5 min) cocluting with standard 12-HETE 
and a 1.6-min fraction (elution rime approximately 8.4 - I 0 min) 
coeluting with standard AA were collected. The 12-H ETE fraction 
was evaporated and repurified by straight phase HPLC on a 
25 em X 4.9 mm Nucleosil 50 - 5 J1m column (Hichrom, Read-
ing, UK) eluted with hexane/propan-2-ol/methanolfacetic acid 
(95: 3:2:0.1 by vol) at I ml/min-1. A 1-min fraction (elution time 
approximately 5 - 6 min) cocluting with standard 12-HETE was 
collected. Fractions containing the purified AA and 12-HETE were 
evaporated and reacted with ethereal methanolic diazomethane fol-
lowed, in the case of 12-HETE samples by bis-trimethylsilyltri-
fluoroaceramide {BSTFA), ro yield arachidonic acid methyl ester 
and 12-HETE methyl ester trimethylsilyl ether (MeTMS) deriva-
tives. The endogenous AA and 12-HETE in these samples was 
quantified by stable ismope dilution selecred ion monitoring gas 
chromatography- mass spectrometry (GCMS). GC was carried our 
on a 25 m X 0.32 mm Hewlett Packard non-polar phase {SE30 
equivalent) silica column interfaced with a VG 305 mass spectrome-
ter. Data were recorded under electron impact conditions at 45 eV. 
The ions monitored were m/z 295 and 30 I for the MeTMS deriva-
tives of 12-HETE and its deuterated internal standard and m/z 361 
and 369 for che methyl ester of AA and its deuterated internal 
standard, respectively. The absolute amounts of endogenous AA 
and 12-H ETE in each sample were determined by reference to 
standard calibration curves. 
The second chamber fluid sample (B) from each sire was acidified, 
extracted with ethyl acetate, and partitioned between n-heptane and 
methanol as described above. The methanolic residue was purified 
by reversed phase HPLC on rhe above column eluted with metha-
nolfwaterfacetic acid {85: 15 :0.01 , by volume) at 0.8 ml/ min-•. A 
1.5-min fraction co-eluting with standard L TB~ (approximately 5.8 
- 7.3 min) as well as a 1.5-min blank fraction eluting immediately 
after this were collected. Because ng amounts of standard LTB~ 
were injected during column calibration, bur pg amounts of endog-
enous L TB4 activity recovered from chamber fluid samples, care 
was exercised to avoid concammarion of H PLC injection apparatus 
w1th standard L TB •. Following evaporation and vacuum desicca-
tion, fraction residues were redissolved in 0.3 ml minimal essential 
medium (MEM) buffered w1th 30 mM HEPES and 0 .1 ml aliquots 
assayed in duplicate without further dilution and after fivefold dilu-
tion in an agarose microdroplet neutrophil chemokinesis assay 
[ 12,29). The LTB~ equivalents in each sample were determined by 
reference to standard L Til~ dose response curves (3 - 1 00 pg L TB~ 
per assay), the value obtained for the blank fraction being subtracted 
from that obtained for rhe fraction coeluting with standard L TB~. 
All samples from the same volunteer were quantified in the same 
m1crodroplet assay. 
A~ no imernal standard was used in the LTB~ assay, correction for 
losses during extraction and purification could not be made. Experi-
ments to determine the recovery of standard L TB~ and the interas-
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say co-efficu.•nt of vananon were therefore earned out. Standard 
L TB~ (100 pg} was added to 1 ml PBS, which was actdified, ex-
tracted mro ethyl acetate, parntioned between n-heptane and meth-
anol, and punfied by reversed phase HPLC as descnbed above for 
the LTD~ analysts. Blank fracnons and fractions coelutmg wtth 
standard LTB~ (1.5 ml each) were collected and LTB~ equivalent~ 
quanrtlied as de~crrbed. 
Reversed phase HJ>LC of lonapalene itself showed that 1t eluted 
at approxunately 6.8 mm in the HPLC system used for purificanon 
of L TB~ and would therefore contaminate the fractions (approxi-
mately 5.8 - 7.3 mm} collected for LTB~ analysis. h wa~ therefore 
necessary ro dctcrmmc whether lonapalene affected the responses to 
LTB~ in the agarose mJcrodroplct assay. Sarurated solutions oflona-
palenc were prepared by sonicating an excess of crystalline lonapa-
lene Ill II EPES-buffered MEM for 15 min. Following centrifuga-
tion, supernatant was used as medium in the microdroplet assay after 
2- ro 16-fold dilution, and responses to 100 pg LTB~ were com-
pared With those seen 111 the absence oflonapalene. In further exper-
iments, four normal male volunteers (aged 25 - 44 year~} each 
apphcd 2% lonapalene ointment twtce daily to a fixed area of the 
antenor thtgh, for 5 d. After thts time a chamber fluid sample (1 rnl) 
was obtamcd from the lonapalenc treated area, acidified, extracted, 
and purified bv reversed phase HPLC as described for the L TB~ 
analysts above. Followmg evaporation and vacuum dcstccatton of 
the 1.5 mm HPLC fraction, whtch coeluted with standard L TB4, 
180 pg standard L TB. was added ro each residue that was redJ\-
solved 1n 0.3 ml HEJ>ES-buffered MEM. Aliquots (0.1 ml, each 
containing 60 pg LTB~} were assayed i.n duplicate in the agarose 
m1crodroplct assay and the responses compared with tho!>e seen in a 
standard L TB. dose-response curve. These experiments were de-
signed with the knowledge that chamber fluid sample~ from normal 
skin contam e1ther no measurable LTB~ or only trace amounts [5]. 
Sta tistical Analysis The significance of the difference between 
clinical !>Cores for erythema, induration, and scaling was determmed 
by Wilcoxon's S1gned Rank Test for non-parametric paired data. 
Paired t tests were med to compare the levels of AA, 12-HETE,and 
LTB •. 
Mater ials LTB4 was a g1ft of Dr. J. Rokach (Merck Frosst, 
Pmnrc Claire-Dorval, Canada). Racemic 12-HETE, racemic 
(5,6,8.9.11,12,14,1S-2Hj 12-HETE and (5,6,8,9,11,12,14,15-
2H]AA were l'rcpared by Dr. P. M. Woollard, as previously de-
scribed [29,30]. 2o/o Lonapalene ointment, ointment base, and crys-
rallmc lonapalene were supplied by Syntex Research (Maidenhead, 
UK). AA (99% purity}, BSTFA, MEM, and HEPES were purchased 
from Sigma (Poole, UK). Diazald for diazomethane generation and 
n-heptane were obtained from Aldrich (Gillingham, UK), and all 
other ~olvents (HPLC grade) from Fison's (Loughborough, UK). 
RESULTS 
One pancnt wa~ removed from the study on day 4 because of the 
onset of burning, tenderness, swelling, lesional erosion, and perilc-
s•onal erythema with follicular accentuation in one Site, subse-
quently shown to be the londpalene-treatcd area. One other patient 
developed erythema and prumus in the lonopalene-treatcd site be-
tween days 24 and 28 of the srudy, but this was not sufficiently 
severe to ncccsmatc Withdrawal. In the nine patients complctmg 
the srudy, climcal grading showed that the summed scores for ery-
thema, induration, and scaling decreased with time in both the 
lonapalenc- and vehicle-treated sites (Fig 1 ). Statistical analys1s by 
Wilcoxon's Signed Rank Test showed that the summed scores for 
lonapalene treated Sites were significantly lower than those for ve-
hicle-treated Sites at 14 (P = 0.02} and 28 (P = 0.01} d. Pretreat-
ment (day 0) score~ for lonapalenc- and vehicle-treated sires were 
identical. At day 4 the mean score for lonapalene-treated s1tes was 
lower than that for velucle-treated sites, but the difference did not 
reach stati!>tical sigmficancc (p > 0.05}. There were no sign1ficant 
changes in haematologic, biochemtcal, and urinary analyses on 
comparison of results obtained before and immediately after the 
trial. 
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Figure 1. Summed chmcal scores (mean ± SEM, n = 9) for untreated 
{dtrsed crrclt), vehiCle- (rlt!sed trimrglt), and lonapalenc- (closd squart) treated 
psomuc plaques unmedtately before and at 4, 14, and 28 dafter starring the 
mal. 
Saturated solutions of lonapalenc 111 HEPES-buffercd MEM, 
when serially diluted 2 to 16 times and used as media in the agarose 
1111crodroplct assay, had no effect on the responses to I 00 pg L TB~ 
(Table 1}. Furthermore, when chamber flu1d obtamed from the 
normal volunteers who had applied 2% lonapalcne ointment twice 
daily wa:. purified as descnbed, the punficd res1ducs had no inhibi-
tory activity towards exogenously added L TB4 in the microdroplet 
assay (Fig 2). These results indtcated that any poss1ble carry-over of 
lonapalene mto the HPLC fractions analyzed would not interfere 
w1th the LTB4 bioassay. 
The recovery of exogenous LTB4 (100 pg) added to 1 ml PBS. 
extracted, purified by IIPLC, and quannfied by the agarose micro-
droplet assay, as described, was 19.5 ± 2.8 pg (mean± SEM, n = 
6}. The coefficient of variation in this experiment, in which the 
final samples were all measured 111 the same m1crodroplct assay, was 
25%. 
The levels of L TB4 , 12-HETE, and AA (mean ± SEM values) in 
chamber fluid samples arc shown in Table II. There was a statisti-
cally significant reduction of L TB~ levels in samples from lonapa-
lenc-treated sites on comparison with vehicle-treated and untreated 
Table I. Effects of a Range of Dilunons of MediUm Saturated 
w1th Lonapalene on Leucocyte Locomotor Responses to L TB~ in 
Agarose Microdroplet Assay 
Dlluuon of Saturated 
Lon~palene Soluuon 
Twofold 
Fourfold 
Eightfold 
16-fold 
Medtum Without lonapalene 
Chemokmcric Movement (mm) 
tn Rcspome to 100 pg LTB,• 
0.88 ± 0.15 
0.95 ± 0.13 
0.90 ± 0.14 
0.86± 0.1 I 
0.91 ± 0.13 
• V>lue.represent me>n ± SEM of four expcnments (two earned out &n duphcate a.nd 
two m quadruplic.11e). 
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Figure 2. Etlrct~ of matcnal m appropnate fractiOns after H PLC pun fica-
cion oi chamber fhud sample~ from lonapalenc-rreated normal ~km, on 
re~pomcs to exogenously added L TB. m the agarose microdropler assay. A 
standard L TB. dme-rcsponsc curve i~ shown, each point (clt~srd drclr) rt'prc-
~cnttng thc mean of dupltcatc csumations. Fractions (1.5 mm) cocluting 
wtth standard L TB. after reversed-phase HPLC of extracts of cham her f!utd 
from lonapalcnc-trc.ltccl normal ;km were redissolved in HEPES-buffered 
MEM (0.3 ml) Jnd e'ogenous L TB4 added as described. Dupltcatc altquots 
(0. I ml) contatmn~ 60 pg C"xogcnously added LT.B, were tested in the same 
assay (clasrd squarl': mean result of analysis of samples from the four normal 
volumccrs; SEM ts wtthm the margms of the symbol). Background acttvtcy 
in the assay ts shown (••rnr rirde) 
sites at 4 d, and on comparison with vehicle-rreated sites at 14 d. In 
contrast to the effects on L TB4 , there were no significant changes in 
the mean levels of 12-HETE and AA in samples from lonapalene 
treated site~ at either nme point. 
In Table III the clmical and pharmacologic effects of lonapalene 
in mdividual panents arc compared. It can be seen that reduction in 
the chamber fluid L Tn.level after 14 d oflonapalene tre:mnent was 
associated with a subsequent reduction in clinical score in seven out 
of the nine patient~ completing the trial. 
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Table ill. Reouction in Chamber Fluid Levels of LTB~ ar 14 d 
Compared with Reduction 111 Ch111cal Score at 28 d Followmg 
Lonapalene Treatment, in lnd1v1dual Patients 
L TB4 Equtvalents 
(pg/ sample) at 14 d Cltmcal Score at 28 d 
Pattent Number v· L• V-L' v• L' V-L' 
I 78 17 61 4 1.5 2.5 
2 87 42 45 9 5 4 
3 87 0 87 8 7 I 
4J 81 5 76 I I 0 
5 102 53 49 8 5 3 
6 26 0 26 8 6 2 
7J 32 32 0 4.5 2 2.5 
8' 
9 90 18 72 5 4 I 
10 87 6 81 5 (},5 4.5 
• Values for vehicle-created sttes. 
• Values for lonapalene-treated sttes. 
' Values for lonapalene-tr.,.ted sates subtucted from values for vehtcle-tteaced sates, 
demonuraung addirion.:al effects of drug over vehacle alone. 
'In p.tttents 4 and 7, V-L for L Tll, equtvalents dad not correlate wath V-L ford maca! 
SCOit". 
'Pauent 8 wtthdrew from the mal, as descnbed tn Mtthodr. 
DISCUSSION 
Prev10us clmical studies have demonstrated the therapcuuc efficacy 
of top1cally applied lonapalene in psoriasis. Lassus and Forssrrom 
[27], in a double-blind comparison between 1% lonapalene gel and 
0.025% fluocinolone acetonide gel, demonstrated equivalent thera-
peutic responses after 4 weeks of treatment, although no compari-
sons were made with plaques treated with vehicle alone. Jansen et al 
[28], in a study presented as a poster and pubhshed in abstract form, 
showed that 0.5% lonapalene ointment was as effective as 0.025% 
fluocinolone acetonide ointment, and significantly superior to ve-
hicle alone. In their study of 19 psoriatic patients, one-tlmd were 
reported to experience local irntant reactions to the lonapalene 
preparation. 
The present clmical and pharmacologic study was lumted to ten 
patients in view of the quannry of analyncal work required. For 
example, quantification of L TB4 , 12-HETE, and AA, as described, 
mvolved recovery of six paired chamber flllld samples, two stage 
hp1d extracnon procedures, and a total of 18 HPLC purification 
steps per volunteer, prior to bioassay, denvatization, and GC-MS 
analys1s of punfied material. Nevertheless, statistically significant 
improvement was found when the summed scores for erythema, 
induration, and scaling from sites treated with 2% lonapalene oint-
ment were compared with those from veh1cle-rreated lesiOns at 14 
and 28 d (Fig 1). Figure 1 shows a mean reduction in clinical score 
of approximately 50% when the results for lonapalene-treated sires 
are compared with those for untreated sites at 28 d, an outpatient 
clirucal response which may be potentially useful. A s1gnificant 
vehicle effect is also demonstrated in Fig 1. This finding highlights 
Table n. Levels of L TB. Equivalents, 12-HETE, and AA (mean± SEM) in 0 .9-ml Chamber Fluid Samples from Untreated (U), 
Vehicle- (V), and Lonapalene- (L) Treated Plaques of Psoriasis 
L TB, Equtval~ms (pgj samplc) I 2-IIETE (ng/sampl~)· 
n=9 n=6 
Day~ u v L u v 
4 59± 12 73 ± to• 27 ± 11' 28±6 30± 3 
14 53± 17 74 ± 91 19 ± 6J 30± 5 28 ± 6 
• An .. lysts of umples from sax of the mne volunteers was completed. 
• p > 0.05 on compamon wath umre.red sates. 
• p- 0.01 ~nd 0.006 on comparison wath veh>cle-treated and untreated mes. rr>pccravdy. 
'p - 0.001 and > 0.05 on compan,on with veh>cle-treared and untre•tcd sttcs, respccuvely. 
'p > 0.05 on cornp•nson wath hoth veh>cle-treated and untreoted site> 
L 
22±5' 
23±6' 
AA (ng/sampl~)· 
n""6 
u v L 
164 ± 32 191 ±40 196 ±56' 
187 ±57 191 ±59 123 ± 37' 
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the dtfficulty that may be encountered m toptcal therapeunc mals Ill 
psonam. The emolltenr effect of greasy bases arc hkcly to reduce 
les10nal scores in wluch scalmg and induration are taken tnto ac-
count 
Pharmacologic analysts showed a stgndicanr reduction m 
chamber fluid levels of L TB4-hke material from lonapalene-rreate"d 
vs vehicle"-treated sttes at both 4 and 14 d. In contrast, the chamber 
flutd levch of 12-HETE and AA were not sigmficantly affected by 
lonapalenr treatment, findmgs which agree wtth the ~harmaco­
logtc ~elecnvtty of lonapalene as demonstrated in virro 124]. lnte"r-
esnngly, lonapalene" was shown to elute near L TB4 in the reversed 
phase HPLC punficanon system used prior to quannfication of 
L TB~ by btoassJy. It was therefore necessary to show that lonapa-
lenC' dtd not mhihit the bioassay both by in vitro (Table I) and in vtvo 
(Fig 2) cxprnments. As rrcovery of L TB4 in the assay system used 
was approxunately 20%, the measured levels ofLTB4 equivalents m 
chamber flutd should be muluphed by a factor of about 5 to mdtcate 
actual levrls. 
The abtltty of toptcal lonapalene to reduce mean les10nal LTB.-
like matenal but not 12-HETE or AA (at an early stage of treatment) 
(Table II) prior to the attainment of a significant therapeutic effect, 
as well as the demonstranon that the clinical improvement m re-
sponse to toptcal lonapalene was preceded by a reduction m L TB4 
levels m lcsional samples m seven of nme voluntee"rs (Table III) 
suggest that the therapeutiC effect of 2% lonapalene omtment 1n 
psonam may be related to mhtbinon of L TB4 synthests. These 
results therefore support the vtew that 5-lipoxygenase mhtbttors 
may be usefulm the treatment of psonasis and that L TB4 may be a 
relevant medtator of part of the pathology of this disease.The local 
trritant properrtes of lonapalene may limit its therapeutic apphca-
tton. It is, however, likely that the clmical usc of other 5-hpoxygen-
ase mhtbltors wtll clanfy the importance of these drugs and the 
pathogenic role of L TB4 in psoriasis. 
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